Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
21 studies found for:    Open Studies | "Respiratory Syncytial Virus Infections"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Viral Inhibition in Children for Treatment of RSV
Condition: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Interventions: Drug: AK0529;   Drug: Placebo
2 Recruiting Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: REGN2222;   Drug: Placebo
3 Recruiting A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV Vaccine (GSK3003891A) formulation 1;   Biological: RSV Vaccine (GSK3003891A) formulation 2;   Biological: RSV Vaccine (GSK3003891A) formulation 3;   Drug: Placebo (Formulation buffer S9b)
4 Recruiting Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 1030s vaccine;   Biological: Placebo
5 Recruiting Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
6 Not yet recruiting A Study to Evaluate Safety and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 17 Months
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV vaccine (GSK3389245A) low dose;   Biological: RSV vaccine (GSK3389245A) middle dose;   Biological: RSV vaccine (GSK3389245A) high dose;   Drug: Placebo LD;   Drug: Placebo MD;   Drug: Placebo HD
7 Recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
8 Recruiting A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897;   Drug: Placebo
9 Recruiting RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: MVA-BN-RSV;   Other: Placebo
10 Not yet recruiting RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: MVA-BN-RSV;   Other: Placebo
11 Not yet recruiting A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALS-008176;   Drug: Placebo
12 Recruiting A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV F vaccine with adjuvant;   Biological: Formulation buffer
13 Recruiting Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46cpΔM2-2 vaccine;   Biological: Placebo
14 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
15 Recruiting A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection
Conditions: Respiratory Syncytial Virus Infections;   Virus Diseases
Interventions: Drug: JNJ-53718678;   Drug: Placebo
16 Recruiting A Study of ALS-008176 in Infants Hospitalized With RSV
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALS-008176;   Drug: Placebo
17 Recruiting A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers
Conditions: Respiratory Syncytial Virus Infections;   Influenza, Human
Interventions: Biological: RSV A Memphis 37;   Biological: Influenza A/California/04/2009
18 Recruiting Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
Conditions: Lower Respiratory Tract Infection;   Respiratory Syncytial Virus Infections
Intervention:
19 Recruiting Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Condition: Respiratory Syncytial Virus
Interventions: Drug: Presatovir;   Drug: Placebo
20 Recruiting Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
Condition: Respiratory Syncytial Virus (RSV) Infection
Interventions: Drug: BTA-C585 oral capsule;   Drug: Matching placebo capsules

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.